Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 18:12:295.
doi: 10.1186/1471-2407-12-295.

Aggressive local treatment containing intraoperative radiation therapy (IORT) for patients with isolated local recurrences of pancreatic cancer: a retrospective analysis

Falk Roeder  1 , Carmen Timke, Matthias Uhl, Gregor Habl, Frank W Hensley, Markus W Buechler, Robert Krempien, Peter E Huber, Juergen Debus, Jens Werner
Affiliations

Aggressive local treatment containing intraoperative radiation therapy (IORT) for patients with isolated local recurrences of pancreatic cancer: a retrospective analysis

Falk Roeder et al. BMC Cancer. .

Abstract

Background: To evaluate the use of intraoperative radiation therapy (IORT) in the multimodality treatment of patients with isolated local recurrences of pancreatic cancer.

Methods: We retrospectively analyzed 36 patients with isolated local recurrences of pancreatic cancer who have been treated with a combination of surgery, IORT and EBRT. Median time from initial treatment to recurrence was 20 months. All patients were surgically explored. In 18 patients a gross total resection was achieved, whereas the other half received only debulking or no resection at all. All patients received IORT with a median dose of 15 Gy. Additional EBRT was applied to 31 patients with a median dose of 45 Gy, combined with concurrent, mainly gemcitabine-based chemotherapy.

Results: Median follow-up in surviving patients was 23 months. Local progression was found in 6 patients after a median time of 17 months, resulting in estimated 1- and 2-year local control rates of 91% and 67%, respectively. Distant failure was observed in 23 patients, mainly in liver or peritoneal space. The median estimated progression-free survival was 9 months with 1- and 2-year rates of 40% and 26%, respectively. We found an encouraging estimated median overall survival of 19 months, transferring into 1- and 2-year rates of 66% and 45%. Notably 6 of 36 patients (17%) lived for more than 3 years. Severe postoperative complications were found in 3 and chemoradiation-related grade III toxicity in 6 patients. No severe IORT related toxicity was observed.

Conclusion: Combination of surgery, IORT and EBRT in patients with isolated local recurrences of pancreatic cancer resulted in encouraging local control and overall survival in our cohort with acceptable toxicity. Our approach seems to be superior to palliative chemotherapy or chemoradiation alone and should be further investigated in a prospective setting specifically addressing isolated local recurrences of pancreatic cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment schedule. OP: operation, neoadj. : neoadjuvant, adj. : adjuvant, EBRT : external beam radiation therapy, IORT : intraoperative radiation therapy.
Figure 2
Figure 2
Local control.
Figure 3
Figure 3
Progression-free survival.
Figure 4
Figure 4
Overall survival.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225–249. doi: 10.3322/caac.20006. - DOI - PubMed
    1. Chang BW, Saif MW. Stereotactic body radiation therapy (SBRT) in pancreatic cancer : Is it ready for prime time? J Pancreas. 2008;9:676–682. - PubMed
    1. Saif MW. Controversies in the adjuvant treatment of pancreatic cancer. J Pancreas. 2007;8:545–552. - PubMed
    1. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer – a randomized controlled trial. JAMA. 2007;297:267–277. doi: 10.1001/jama.297.3.267. - DOI - PubMed
    1. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirybayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511–518. doi: 10.1016/j.gassur.2005.09.016. - DOI - PubMed